RecruitingPhase 2NCT05069857

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Studying Squamous cell carcinoma of the oral tongue

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai Jiao Tong University School of Medicine
Principal Investigator
Lai-ping Zhong, MD, PhD
Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Intervention
Camrelizumab (anti-PD-1 inhibitor)(drug)
Enrollment
46 enrolled
Eligibility
18-75 years · All sexes
Timeline
20212028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05069857 on ClinicalTrials.gov

Other trials for Squamous cell carcinoma of the oral tongue

Additional recruiting or active studies for the same condition.

See all trials for Squamous cell carcinoma of the oral tongue

← Back to all trials